Bristol-Myers Squibb Company (BMY) Presents at 45th Annual TD Cowen Health Care Conference (Transcript)Seeking Alpha • 03/04/25
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers SquibbAccesswire • 03/04/25
The Artificial Intelligence Party Over for Now? Safe 4%+ High-Yield Dividend Blue Chips Are On Sale24/7 Wall Street • 02/28/25
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closingPRNewsWire • 02/20/25
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung CancerBusiness Wire • 02/19/25
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque PsoriasisBusiness Wire • 02/16/25
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 02/11/25
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone LymphomaBusiness Wire • 02/10/25
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock DownSeeking Alpha • 02/07/25
Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call TranscriptSeeking Alpha • 02/06/25
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 OutlookZacks Investment Research • 02/06/25
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q4 EarningsZacks Investment Research • 02/06/25
Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/06/25